Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

You may be eligible if

• Inclusion:
• 1. Parent/Legal Guardian can understand the consent process and is willing to provide informed consent/HIPAA authorization prior to the conduct of any study-related procedures. When applicable, the minor participant is willing to provide assent.
• 2. Participant has clinical diagnosis of non-mosaic DS.
• 3. Participant is between 6 and 12 years of age (inclusive) at time of consent.
• 4. Participant weight is ≥ 25 kg.
• 5. Participant has clinically significant symptoms of hyperactivity, inattention and impulsivity manifested as minimum scores of the following rating scales within 30 days of randomization:
• 1. A minimum score of 18 on the parent-reported ABC-H subscale, AND
• 2. A minimum score of moderate or greater (≥ 4) on the clinician reported Clinical Global Impression Severity (CGI-S) score specific to hyperactivity, inattention and impulsivity behaviors.
• 6. Participant has co-morbid medical screening and clearance to proceed with a non-stimulant medication trial with GIR within 30 days of randomization.
• 7. Participant is willing and able to comply with study procedures, including adherence to medication dosing schedule.
• Exclusion:
• 1. Participant has received guanfacine (any formulation) within 30 days of randomization.
• 2. Participant has received any of the following concomitant medication classes within 30 days of randomization:
• 1. Strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole)
• 2. Strong CYP3A4 inducers (e.g., avasimibe, carbamazepine, phenytoin, rifampin, and St. John's wort)
• 3. Participant has a psychiatric comorbidity, such as major depressive disorder, bipolar disorder, obsessive-compulsive disorder, or a psychotic disorder, that requires a pharmacological treatment other than guanfacine
• 4. For participants ≥ 8 years old at the time of consent, participant has a history of suicidality or positive screen on Ask Suicide-Screening Questions (asQ) Tool.
• 5. Participant is currently in or plans to participate in another interventional study.
• 6. Participant has a known hypersensitivity to guanfacine.
• 7. Participant has had a previous guanfacine treatment failure, as determined by their primary treating physician.
• 8. Participant has had a change in another medication intended to treat symptoms of hyperactivity, inattention, and impulsivity within the last 2 weeks.
• 9. Participant has had a seizure within the last 6 months.
• 10. Participant has had a change in their anti-convulsant dose within the last 4 weeks.
• 11. Participant has a cardiac-related condition including:
• 1. Significant symptomatic bradycardia;
• 2. 2nd degree or 3rd degree (complete) heart block;
• 3. Baseline heart rate (HR) or systolic blood pressure (BP) \> 2 standard deviations (SD) below mean for age as determined by medical examination;
• 4. History of aborted sudden cardiac death, unexplained syncope or near syncope, or historical use of a pacemaker as determined by medical history will require clearance by cardiology prior to enrollment;
• 5. Known history of congenital heart disease which requires ongoing care for monitoring or management will require clearance by cardiology prior to enrollment.
• 13. Participant has untreated thyroid disease.
• 14. Participant has a known hepatic impairment defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2x the upper limit of normal (ULN) for age.
• 15. Participant has known impending or renal failure defined as:
• 1. Anuria diagnosed within 12 hours prior to enrollment;
• 2. Requiring renal replacement therapy.
• 16. Participant is pregnant.
• 17. Participant has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study.